Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
16.02M | 0.00 | 0.00 | 0.00 | 12.06K | Gross Profit |
16.02M | -4.03M | -134.03K | -227.27K | -188.16K | EBIT |
4.51M | -12.59M | -12.31M | -16.94M | -8.19M | EBITDA |
5.70M | -12.35M | -13.55M | -13.73M | -6.65M | Net Income Common Stockholders |
3.59M | -12.51M | -13.58M | -16.39M | -8.09M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
26.79M | 2.45M | 5.96M | 7.85M | 1.19M | Total Assets |
36.48M | 13.71M | 18.68M | 18.06M | 15.16M | Total Debt |
57.17K | 106.89K | 105.78K | 209.41K | 362.12K | Net Debt |
-3.74M | -2.35M | -5.86M | -7.65M | -823.56K | Total Liabilities |
10.72M | 7.60M | 7.27M | 8.83M | 8.16M | Stockholders Equity |
25.76M | 6.11M | 11.41M | 9.22M | 7.00M |
Cash Flow | Free Cash Flow | |||
8.55M | -9.56M | -10.43M | -10.95M | -7.45M | Operating Cash Flow |
8.56M | -9.56M | -10.43M | -10.89M | -7.32M | Investing Cash Flow |
-22.66M | 0.00 | 6.38K | -157.02K | -244.44K | Financing Cash Flow |
15.50M | 5.97M | 8.62M | 17.80M | 5.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
50 Neutral | $9.11M | ― | -45.38% | ― | -48.61% | 32.18% | |
48 Neutral | $6.36B | 1.09 | -49.92% | 2.63% | 17.17% | 0.95% | |
48 Neutral | $8.50M | 3.71 | 22.56% | ― | ― | ― | |
42 Neutral | $7.95M | ― | -184.99% | ― | -1.54% | -7.20% | |
38 Underperform | $7.27M | ― | -534.03% | ― | ― | 23.65% |
Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial of KIO-301 for treating retinitis pigmentosa, aiming to restore vision in patients with severe vision loss. The ABACUS-2 trial will assess the drug’s safety and efficacy across multiple centers in Australia, utilizing a unique photoswitch mechanism that could work for various gene mutations associated with retinal diseases. This innovative approach, supported by Théa Open Innovation, offers hope for a breakthrough in treating inherited retinal conditions.